medigraphic.com
ISSN 1561-302X (Print)

2020, Number 3

<< Back Next >>

Rev cubana med 2020; 59 (3)

Safety of chloroquine and hydroxychloroquine for treating COVID-19 patients

Rodríguez VEC, Hernández-García OL, Denis PDA

Language: Spanish
References: 28
Page: 1-9
PDF size: 334.05 Kb.


ABSTRACT

Introduction: Chloroquine and its analogue hydroxychloroquine have shown antiviral and anti-inflammatory effects, so it could be an alternative treatment to the new SARS-CoV-2 coronavirus.
Objective: To describe the safety of chloroquine and hydroxychloroquine for treating COVID-19 according to current scientific evidence.
Method: We used the search strategy for coronavirus OR COVID-19 OR SARS-CoV2 AND Chloroquine AND Hydroxychloroquine, and Pubmed, SciELO, Lilacs, Cochrane Library and Web of Science databases were used. Thirty two bibliographic references were recovered, selection followed the selection criteria.
Conclusions: The efficacy of chloroquine and hydroxychloroquine has not been fully proven, since the results have not been conclusive and differences have been found between them, In addition to the fact that sufficiently representative samples have not been studied. The adverse reactions of these drugs, and the cardiovascular ones are the most dangerous, should not be ignored since they have occurred with certain frequency and in relation to the administered dose. Therefore, it is necessary to carry out more randomized clinical trials, with greater control of biases and representative samples, to evaluate the efficacy and safety of these drugs.


REFERENCES

  1. Cheng VC, Lau SK, Woo PC, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev. 2007;20(4):660-94. DOI: https://dx.doi.org/10.1128/CMR.00023-07

  2. Zhong NS, Zheng BJ, Li YM, Poon LLM, Xie ZH, Chan KH, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China. Lancet. 2003;362(9393):1353-58. Doi: https://dx.doi.org/10.1016/s0140-6736(03)14630-2

  3. Keogh Brown MR, Smith RD. The economic impact of SARS: how does the reality match the predictions? Health Policy. 2008;88(1):110-20. DOI: https://dx.doi.org/10.1016/j.healthpol.2008.03.003

  4. Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. The New England Journal of Medicine. 2012;367(19):1814-20. DOI: https://dx.doi.org/10.1056/nejmoa1211721

  5. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470-73. DOI: https://dx.doi.org/10.1016/S0140-6736(20)30185-9

  6. Hernández García OL, Rodríguez Venegas EC. Cloroquina e Hidroxicloroquina en el tratamiento de la COVID-19. Revista 16 de abril. 2020[acceso: 10/02/2020];59(276):e962. Disponible en: Disponible en: http://www.rev16deabril.sld.cu/index.php/16_4/article/view/962

  7. Ling Z, Xu X, Gan Q, Zhang, Luo L, Xiaoping Tang X, et al. Asymptomatic SARS-CoV-2 infected patients with persistent negative CT findings. Eur J Radiol. 2020. DOI: https://dx.doi.org/10.1016/j.ejrad.2020.108956

  8. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care. 2020;24(242):108. DOI: https://dx.doi.org/10.1186/s13054-020-2833-7

  9. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42. DOI: https://dx.doi.org/10.1001/jama.2020.2648

  10. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med.2020;8(5):475-80. DOI: https://dx.doi.org/10.1016/S2213-2600(20)30079-5

  11. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2(69):1-10. DOI: http://dx.doi.org/10.1186/1743-422X-2-69

  12. Gautret P, Lagier LC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of anopen-label non-randomized clinical trial, International Journal of Antimicrobial Agents. 2020;105(949):1-24. DOI: https://dxdoi.org/10.1016/j.ijantimicag.2020.105949

  13. Slater AFG. Chloroquine: Mechanism of drug action and resistance in plasmodium falciparum. Pharmacology & Therapeutics. 1993;57(2-3),203-35. DOI: https://dx.doi.org/10.1016/0163-7258(93)90056-J

  14. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004;323(1):264-68. DOI: https://dx.doi.org/10.1016/j.bbrc.2004.08.085

  15. Zhonghua Jie, He He Hu, Xi Za Zhi. Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Airi Clip. 2020[acceso: 10/02/2020];43(0):E019. Disponible en: Disponible en: https://www.unboundmedicine.com/medline/citation/32075365/[Expert_consensus_on_chloroquine_phosphate_for_the_treatment_of_novel_coronavirus_pneumonia]

  16. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(1). DOI: https://dx.doi.org/10.1038/s41422-020-0282-0

  17. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience Trends. 2020;14(1):72-73. DOI: https://dx.doi.org/ 10.5582/bst.2020.01047

  18. Mandeep R Mehra. La cloroquina y la hidroxicloroquina aumentan el riesgo de muerte en pacientes con coronavirus. La Habana: Infomed Ecimed . 2020[acceso: 27/05/2020]. Disponible en: Disponible en: http://www.sld.cu/node?iwp_post=2020%2F05%2F25%2FLa%20cloroquina%20y%20la%20hidroxicloroquina%20aumentan%20el%20riesgo%20de%20muerte%20en%20pacientes%20con%20coronavirus%2F184103&iwp_ids=1_84103&blog=1_aldia

  19. Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ. 2020;192(17): 450-53. DOI: https://dx.doi.org/10.1503/cmaj.200528

  20. Chen J, Danping L, Li L, Ping L, Qingnian X, XIA L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci). 2020;49:1-10. DOI: https://dx.doi.org/10.3785/j.issn.1008-9292.2020.03.03

  21. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. Medrxiv. 2020;200(4):1-11. DOI: https://dx.doi.org/10.1101/2020.03.22.20040758

  22. Molina JM, Delaugerre C, Goff J Le. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with Severe COVID-19 Infection. Medicine Mal Infect. 2020;50(4):384. DOI: https://dx.doi.org/10.1016/j.medmal.2020.03.006

  23. Mahévas M, Tran VT, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020;369(2020):1844. DOI: https://dx.doi.org/10.1136/bmj.m1844Cortegiani

  24. A Mariachiara Ippolito G, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care. 2020;57:279-83. DOI: https://dx.doi.org/10.1016/j.jcrc.2020.03.005

  25. Silva MG, Almeida FF, Sousa V, Araújo MA, Cardoso G, Brito M, et al. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). MedRxiv. 2020[acceso: 10/02/2020];200(5):1-31. Disponible en: Disponible en: https://www.medrxiv.org/content/10.1101/2020.04.07.20056424v1.full.pdf

  26. Chorin E, Dai M, Shulman E. The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin. medRxiv. 2020;200 (4):1-11. DOI: https://dx.doi.org/10.1101/2020.04.02.20047050

  27. Gérard A, Romani S, Fresse A, Viard D, Parassol N, Granvuillemin G, et al. “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapies. 2020[acceso: 23/02/2020];45(3):1-9. https://dx.doi.org/10.1016/j.therap.2020.05.002

  28. Protocolo de Actuación Nacional para la COVID-19 versión 1.4. Minsap. 2020[acceso: 10/02/2020]. Disponible en: Disponible en: https://fi-les.sld.cu/editorhome/files/2020/05/MINSAP_Protocolo-de-Actuaci%-C3%B3n-Nacional-para-la-COVID-19_versi%C3%B3n-1.4_mayo-2020.pdf




2020     |     www.medigraphic.com